Scientific Sessions 2026 Daily News: Saturday, Nov. 7

4 SCIENTIFIC SESSIONS DAILY NEWS | Saturday, Nov. 7, 2026 Scientific consensus is growing that the endothelium plays a more active role in human health than previously understood. In fact, researchers are increasingly recognizing the vascular endothelium as one of the body’s most influential organ systems and a key driver of cardiovascular and systemic disease, said Jason Kovacic, MD, PhD, FAHA, noting that it was once regarded as little more than a passive lining of blood vessels. Kovacic explored that disconnect Friday during the session titled “The Thrombo-Inflammatory Axis: Bridging the Vessel Wall, Blood and Bedside.” The endothelium helps regulate inflammation, blood flow, thrombosis and numerous disease processes throughout the body, Kovacic said during his presentation, “The Host: Endothelial Dysfunction as the Architect of Disease.” “Data have now become compelling that the endothelium is a critical mediator of multiple diseases that include not only numerous vascular disease states, but systemic conditions and disease states as far ranging as diabetes, systemic inflammatory responses and obesity,” said Kovacic, a clinical professor of cardiology at both the Icahn School of Medicine at Mount Sinai in New York and the Victor Chang Cardiac Research Institute in Sydney, Australia. “Our understanding of the endothelium has evolved from that of a passive cell monolayer to a host and fundamental architect of disease.” Kovacic’s presentation focused on the biological mechanisms driving endothelial dysfunction. Through lab research, his team has examined endothelial-to-mesenchymal transition (EndMT), a process in which endothelial cells change in ways that contribute to vascular disease development. Researchers have identified the signaling molecule SMAD3 as a critical regulator of this process, Kovacic said. Experimental studies in cell-based and animal models showed that inhibiting SMAD3 can block EndMT and reduce neointima formation, a key factor in blood vessel narrowing after surgery. Researchers also reported improvements in vein graft patency in large-animal studies, findings that may pave the way for future therapeutic applications in vascular medicine. His team is now working to translate these discoveries into clinical practice. “The endothelium is a complex organ system. There are multiple mechanistic pathways involved that reflect the diversity of vascular and systemic disease states that the endothelium orchestrates. Accordingly, the relevant mechanistic pathways involved are as diverse as the diseases themselves,” Kovacic said. Kovacic also addressed the persistent challenge of residual cardiovascular risk. Although widely used lipid-lowering therapies, including statins and PCSK9 inhibitors, have significantly reduced cardiovascular events by lowering LDL cholesterol, Kovacic said many patients continue to experience heart attacks, strokes and other vascular complications despite optimal cholesterol management. “This residual risk is partly driven by a thrombo-inflammatory loop where chronic, low-grade inflammatory and localized pro-thrombotic signaling conspire to transform a healthy, antithrombotic luminal surface into an active participant in atherothrombosis,” Kovacic said. Beyond the cardiovascular implications, Kovacic called for a broader rethinking of endothelial Endothelium emerges as central driver of disease Jason Kovacic, MD, PhD, FAHA Functioning as a dynamic organ system, it regulates inflammation, blood flow, thrombosis and numerous disease processes throughout the body. See ENDOTHELIUM, page 18 © NewAmsterdam Pharma B.V. 2026 09/26 UM-US--0028 NewAmsterdam Pharma is committed to developing novel, nonstatin, oral therapies that will potentially reduce patients’ ASCVD risk. ACC, American College of Cardiology; AHA, American Heart Association; ASCVD, atherosclerotic cardiovascular disease; CVD, cardiovascular disease. Reference: 1. Palaniappan LP, Allen NB, Almarzooq ZI, et al. 2026 heart disease and stroke statistics: a report of US and global data from the American Heart Association. Circulation. 2026;153:e275-e906. doi:10.1161/CIR.0000000000001412 2. Blumenthal RS, Morris PB, Gaudino M, et al. 2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of dyslipidemia: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2026;153:e00-e00. doi:10.1161/CIR.0000000000001423 NewAmsterdam Pharma is dedicated to Defusing ASCVD risk IT’S TIME TO EXPECT MORE Each day >2500 US adults die of CVD,1 despite available lipid therapies Visit us at BOOTH #3102 The 2026 ACC/AHA guideline broadens the focus beyond LDL-C.2 Scan to see why looking beyond LDL-C matters. Paid Advertisement

RkJQdWJsaXNoZXIy MjI2NjI=